Reported Saturday, Nurix Therapeutics Presents Phase 1 Data For BTK Degrader NX-5948 In Patients With Relapsed/Refractory Waldenstrom's Macroglobulinemia
Portfolio Pulse from Benzinga Newsdesk
Nurix Therapeutics presented promising Phase 1 data for its BTK degrader NX-5948, showing significant clinical activity in patients with relapsed/refractory Waldenstrom's Macroglobulinemia. The data, presented at IWWM-12, showed a 77.8% response rate among evaluable patients.
October 21, 2024 | 7:42 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Nurix Therapeutics' Phase 1 trial data for NX-5948 shows a 77.8% response rate in Waldenstrom's Macroglobulinemia patients, indicating strong clinical activity and potential for further development.
The positive Phase 1 trial results for NX-5948, with a high response rate, suggest strong potential for Nurix Therapeutics' drug in treating Waldenstrom's Macroglobulinemia. This could lead to increased investor interest and a positive impact on NRIX's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100